Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alterity TherapeuticsASX:ATH +2.83%28 12-1 Month Momentum % is -17.86% as of Aug. 01, 2026. GuruFocus rates ASX:ATH with a GF Score™ of 28/100. Among 1,358 Biotechnology companies, Alterity Therapeutics ranks worse than 50.29% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-01), Alterity Therapeutics's 12-1 Month Momentum % is -17.86%.
The industry rank for Alterity Therapeutics's 12-1 Month Momentum % or its related term are showing as below:
ASX:ATH's 12-1 Month Momentum % is ranked worse than 50.29% of 1358
companies
in the Biotechnology industry
Industry Median: -17.575
vs ASX:ATH: -17.86
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Alterity Therapeutics 12-1 Month Momentum % Related Terms
ASX:ATH vs VRTX, REGN, RVMD: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Alterity Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alterity Therapeutics 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Alterity Therapeutics's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -17.86% mean?
Alterity Therapeutics (ASX:ATH) has a 12-1 Month Momentum % of -17.86% as of Aug. 01, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Alterity Therapeutics and its competitors. According to the industry distribution chart, Alterity Therapeutics ranks #683 out of 1358 companies in the Biotechnology industry, placing it in the top 50.3%.
Is Alterity Therapeutics' 12-1 Month Momentum % too high?
Alterity Therapeutics' current 12-1 Month Momentum % is -17.86%. Based on the distribution chart, Alterity Therapeutics ranks #683 out of 1358 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alterity Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' 12-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alterity Therapeutics ranks #683 out of 1358 companies for 12-1 Month Momentum %. This places Alterity Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current 12-1 Month Momentum % is -17.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current 12-1 Month Momentum % of -17.86%. The current 12-1 Month Momentum % is -17.86%. Alterity Therapeutics' overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current 12-1 Month Momentum % is -17.86% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
28GF Score
Get the complete analysis for ASX:ATH
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATH has been successfully added to your 
